{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:07Z","timestamp":1787387047199,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03672-7","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:20:59Z","timestamp":1781770859000},"page":"4179-4194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Burden of Transthyretin Amyloid Cardiomyopathy on Caregivers and Patients in Japan: A Cross\u2011Sectional Real\u2011World Survey"],"prefix":"10.1007","volume":"43","author":[{"given":"Hiroaki","family":"Kitaoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-9275","authenticated-orcid":false,"given":"Miwa","family":"Enami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Khanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Garratt-Wheeldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"9","key":"3672_CR1","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","volume":"84","author":"H Kitaoka","year":"2020","unstructured":"Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J. 2020;84(9):1610\u201371.","journal-title":"Circ J"},{"issue":"4","key":"3672_CR2","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1002\/ehf2.15311","volume":"12","author":"J Vogel","year":"2025","unstructured":"Vogel J, Jura S, Settelmeier S, Buehning F, Lerchner T, Carpinteiro A, et al. Delays in diagnosis and treatment of ATTR cardiac amyloidosis: a real-world data analysis. ESC Heart Fail. 2025;12(4):2969\u201375.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"3672_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther. 2021;10(1):141\u201359.","journal-title":"Cardiol Ther"},{"issue":"Supplement_1","key":"3672_CR4","doi-asserted-by":"publisher","first-page":"ehaf784","DOI":"10.1093\/eurheartj\/ehaf784.2706","volume":"46","author":"P Collins","year":"2025","unstructured":"Collins P, Melinis N, Chung WY, Hefni F, Hegde R, Ozbey O, et al. Misdiagnosis rates in ATTR-CM patients and associated symptoms. Eur Heart J. 2025;46(Supplement_1):ehaf784.","journal-title":"Eur Heart J"},{"issue":"2","key":"3672_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40119-019-0142-5","volume":"8","author":"I Winburn","year":"2019","unstructured":"Winburn I, Ishii T, Sumikawa T, Togo K, Yasunaga H. Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan. Cardiol Ther. 2019;8(2):297\u2013316.","journal-title":"Cardiol Ther"},{"issue":"22","key":"3672_CR6","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"3672_CR7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357\u201377.","journal-title":"Circulation"},{"issue":"11","key":"3672_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"4","key":"3672_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1253\/circj.CJ-24-0666","volume":"89","author":"M Minamisawa","year":"2025","unstructured":"Minamisawa M, Konishi H, Kitano Y, Abe H, Togo K, Izumiya Y. Patient journey to transthyretin cardiac amyloidosis diagnosis - a Japanese claims database study. circ j. 2025;89(4):432\u201341.","journal-title":"circ j"},{"key":"3672_CR10","doi-asserted-by":"publisher","first-page":"1066224","DOI":"10.3389\/fpsyg.2022.1066224","volume":"13","author":"M Smorti","year":"2022","unstructured":"Smorti M, Ponti L, Soffio F, Argir\u00f2 A, Perfetto F, Zampieri M, et al. Prevalence of anxiety and depression symptoms in a sample of outpatients with ATTR cardiac amyloidosis. Front Psychol. 2022;13:1066224.","journal-title":"Front Psychol"},{"issue":"2","key":"3672_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","volume":"7","author":"M Stewart","year":"2018","unstructured":"Stewart M, Shaffer S, Murphy B, Loftus J, Alvir J, Cicchetti M, et al. Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers. Neurol Ther. 2018;7(2):349\u201364.","journal-title":"Neurol Ther"},{"issue":"1","key":"3672_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40520-024-02750-6","volume":"36","author":"C Fumagalli","year":"2024","unstructured":"Fumagalli C, Ponti L, Smorti M, Pozza F, Argir\u00f2 A, Zampieri M, et al. Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study. Aging Clin Exp Res. 2024;36(1):89.","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"3672_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40119-025-00439-z","volume":"15","author":"F Cappelli","year":"2026","unstructured":"Cappelli F, Ponti L, Smorti M, Hsu K, Damy T, Verheyen N, et al. Functionally limiting symptoms and inability to independently complete daily activities increase the burden felt by caregivers to patients with ATTR-CM. Cardiol Ther. 2026;15(1):43\u201358.","journal-title":"Cardiol Ther"},{"key":"3672_CR14","doi-asserted-by":"publisher","first-page":"1238843","DOI":"10.3389\/fcvm.2023.1238843","volume":"10","author":"L Ponti","year":"2023","unstructured":"Ponti L, Hsu K, Damy T, Villacorta E, Verheyen N, Keohane D, et al. Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study. Front Cardiovasc Med. 2023;10:1238843.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"3672_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/13548506.2023.2280463","volume":"29","author":"L Ponti","year":"2024","unstructured":"Ponti L, Cappelli F, Perfetto F, Maver P, Smorti M. Caregiver\u2019s psychological well-being and quality of relationship with cardiac amyloidosis patients. Psychol Health Med. 2024;29(1):66\u201378.","journal-title":"Psychol Health Med"},{"issue":"11","key":"3672_CR16","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"3672_CR17","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, Doslikova K, Davis VA, Karavali M, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"3672_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"3672_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3672_CR20","unstructured":"Committee NYHAC. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels: Little, Brown Medical Division; 1979."},{"issue":"5","key":"3672_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"3672_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","volume":"35","author":"CP Green","year":"2000","unstructured":"Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas city cardiomyopathy questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3672_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/geront\/20.6.649","volume":"20","author":"SH Zarit","year":"1980","unstructured":"Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of Feelings of Burden. Gerontologist. 1980;20(6):649\u201355.","journal-title":"Gerontologist"},{"key":"3672_CR24","unstructured":"European Pharmaceutical Market Research Association (EphMRA). Code of Conduct 2022 [updated August 2022; cited 06 December 2022. Available from: https:\/\/www.ephmra.org\/code-conduct-aer."},{"key":"3672_CR25","unstructured":"Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare & Ministry of Economy, Trade and Industry. Ethical Guidelines for Medical and Biological Research Involving Human Subjects. 2021. Available from: https:\/\/www.mext.go.jp\/content\/20250325-mxt_life-000035486-01.pdf. Accessed: 13\/01\/2026."},{"key":"3672_CR26","unstructured":"US Department of Health and Human Services. Summary of the HIPAA Privacy Rule 2003 [17 August 2022]. Available from: http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf."},{"key":"3672_CR27","unstructured":"Health Information Technology (HITECH). Health Information Technology Act: US Department of Health and Human Services; 2009 [17 August 2022]. Available from:https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf."},{"key":"3672_CR28","doi-asserted-by":"publisher","first-page":"1595797","DOI":"10.3389\/fcvm.2025.1595797","volume":"12","author":"F Cappelli","year":"2025","unstructured":"Cappelli F, Ponti L, Hsu K, Damy T, Villacorta E, Verheyen N, et al. Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy and their caregivers: a post hoc analysis of an international survey. Front Cardiovasc Med. 2025;12:1595797.","journal-title":"Front Cardiovasc Med"},{"key":"3672_CR29","doi-asserted-by":"publisher","first-page":"1238843","DOI":"10.3389\/fcvm.2023.1238843","volume":"10","author":"L Ponti","year":"2023","unstructured":"Ponti L, Hsu K, Damy T, Villacorta E, Verheyen N, Keohane D, et al. Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study. Front Cardiovasc Med. 2023;10:1238843.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"3672_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13023-022-02601-5","volume":"18","author":"S Acaster","year":"2023","unstructured":"Acaster S, Lo SH, Nestler-Parr S. A survey exploring caregiver burden and health-related quality of life in hereditary transthyretin amyloidosis. Orphanet J Rare Dis. 2023;18(1):17.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3672_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jjcc.2021.10.007","volume":"79","author":"S Takashio","year":"2022","unstructured":"Takashio S, Yamada T, Nishi M, Morioka M, Fujiyama A, Nakashima N, et al. Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy. J Cardiol. 2022;79(1):50\u20137.","journal-title":"J Cardiol"},{"issue":"8","key":"3672_CR32","doi-asserted-by":"publisher","first-page":"462","DOI":"10.15171\/ijhpm.2019.35","volume":"8","author":"N Ikegami","year":"2019","unstructured":"Ikegami N. Financing long-term care: lessons from Japan. Int J Health Policy Manag. 2019;8(8):462\u20136.","journal-title":"Int J Health Policy Manag"},{"issue":"9","key":"3672_CR33","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/ejhf.319","volume":"17","author":"H Shimokawa","year":"2015","unstructured":"Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart Failure as a general pandemic in Asia. Eur J Heart Fail. 2015;17(9):884\u201392.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"3672_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jjcc.2022.01.002","volume":"80","author":"S Takashio","year":"2022","unstructured":"Takashio S, Tokitsu T, Matsukawa M, Sakaino N, Fujimoto K, Sakamoto T, et al. Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: the Kumamoto cardiac amyloidosis survey. J Cardiol. 2022;80(1):49\u201355.","journal-title":"J Cardiol"},{"issue":"3","key":"3672_CR35","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/ejhf.3190","volume":"26","author":"M Grogan","year":"2024","unstructured":"Grogan M, Davis MK, Crespo-Leiro MG, Sultan MB, Gundapaneni B, Stedile Angeli F, et al. Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2024;26(3):612\u20135.","journal-title":"Eur J Heart Fail"},{"key":"3672_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","volume":"141","author":"M Hanna","year":"2021","unstructured":"Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, et al. Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the tafamidis in transthyretin cardiomyopathy clinical trial). Am J Cardiol. 2021;141:98\u2013105.","journal-title":"Am J Cardiol"},{"issue":"2","key":"3672_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"3672_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"3672_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1536\/ihj.23-075","volume":"64","author":"Y Nakaya","year":"2023","unstructured":"Nakaya Y, Ogimoto A, Kitaoka H. Changes in exercise tolerance over time in patients with transthyretin amyloidosis cardiomyopathy treated with tafamidis. Int Heart J. 2023;64(4):647\u201353.","journal-title":"Int Heart J"},{"key":"3672_CR40","doi-asserted-by":"crossref","unstructured":"Bart NK, Bianchi G, Cuddy SAM, Goyal P, Griffin JM, Hummel SL, et al. Cardiac amyloidosis in older adults with a focus on frailty: JACC: advances expert consensus. JACC: Advances. 2025;4(6, Part 1):101784.","DOI":"10.1016\/j.jacadv.2025.101784"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03672-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03672-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03672-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:48Z","timestamp":1787385888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03672-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3672"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03672-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: Hiroaki Kitaoka has received fees from Pfizer Japan Inc., AstraZeneca K.K., Alnylam Japan K.K., Alexion Pharma GK, Bristol Myers Squibb K.K., and Bayer Yakuhin, Ltd. Miwa Enami, Kazumasa Kamei, Jun Hamada, and Akira Yuasa are full-time employees of Pfizer Japan Inc. and hold stocks from Pfizer Inc. Cynthia Khanji is a full-time employee of Pfizer Inc. and hold stocks from Pfizer Inc. Jade Garratt-Wheeldon and Jack Wright are full-time employees of Adelphi Real World.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants provided informed consent at the time of data collection using a checkbox. Data were collected in such a way that patients and physicians could not be identified directly. Physician and patient data were pseudo-anonymized, and a code was assigned when data were collected. Data were aggregated and deidentified before being shared for analysis and publication. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines. This research was submitted to and received ethical exemption from the Pearl Institutional Review Board (IRB study number 2024\u20130328). Each survey was performed in full accordance with relevant legislation at the time of data collection, including the Ethical Guidelines for Medical and Health Research Involving Human Subjects, the US Health Insurance Portability and Accountability Act 1996, and Health Information Technology for Economic and Clinical Health Act legislation.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}